The UK and US have forged a major commercial pact that will preserve zero tariffs on UK medicine shipments being sold in the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase expenditure on medicines through the National Health Service (NHS). This commitment guarantees that import taxes on these vital products will be held at zero for a timeframe of 36 months.
This deal is in response to recent warnings to dramatically increase import taxes on patented pharmaceutical products, with increases discussed reaching one hundred percent.
"This arrangement between the UK strengthens the international landscape for new treatments and establishes much-needed equity to American-British pharmaceutical trade," a statement said.
Commercial Significance
Drugs constitute one of the the United Kingdom's largest export categories to the America, which is by far the largest market for leading companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months to the end of last September, the UK sold pharmaceutical products totaling £11.1bn to the US. This value represented a significant portion of total UK exports in that span.
"This agreement secures employment, increases capital expenditure and sets the stage for the UK to become a global hub for life sciences," a minister stated.
Detailed UK Commitments
The deal entails several specific pledges from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to raise total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to prevent overspending will be limited at fifteen percent. Previously, rebates were more than 20%.
Broader Context
The deal follows a long-running row between the pharmaceutical industry and the UK government over spending levels and approval rates.
These tensions were exacerbated by arguments that American customers were paying several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister acknowledged that the NHS must spend more on medicines, noting that its budget allocation on drugs had decreased as a share of its total funding over the past decade.
